DoKaSch appoints Business Development Manager for U.S. Midwest

Rory Ward is new Business Development Manager for US Midwest. Image: DoKaSch

Six years into the history of DoKaSch subsidiary, California-based DoKaSch Americas Inc., the temperature-controlled active packaging solutions company now has a new Business Development Manager for the U.S. Midwest. Rory Ward has been appointed to increase DoKaSch Temperature Solution’s presence in the U.S. – a country whose pharmaceutical market has a revenue value of more than 630 billion USD and is the largest in the world. The Midwest, in particular, is home to many pharmaceutical and biotech companies and is experiencing significant growth. “Illinois aims to enhance its reputation as a key hub for biomedical research, with Chicago leading the initiative due to its dense concentration of biotech and pharma firms. Contributing to this dynamic growth is Chicago O’Hare Airport, which significantly boosts the region’s economic dynamics by handling approximately 2.2 million metric tons of cargo in 2022, making it a pivotal cargo hub in the United States,” the release details.

Rory Ward, who joins from Airport Logistic Services Group, where he was Operations & Sales Manager, will be responsible for growing the sales of the company’s FAA-certified Opticooler® RKN and RAP containers.

Rory Ward commented: “DoKaSch Temperature Solutions’ Opticooler® provides high-quality and reliable temperature-controlled packaging solutions. I see significant business opportunities in the Midwest Region and am excited to expand the DoKaSch TS network.”

Andreas Seitz, Managing Director of DoKaSch Temperature Solutions, stated: “Rory Ward, a Chicago native, has an in-depth understanding of the Midwest Region market. He is an excellent contact for customers seeking to transport their temperature-sensitive products with our Opticooler®. With Rory Ward as the new Business Development Manager, DoKaSch Temperature Solutions is strengthening its global network and enhancing its engagement in the U.S. pharma market.”



Please enter your comment!
Please enter your name here

See Also